This author has not yet filled in any details.
So far has created 110 blog entries.

Notice of Annual General Meeting of Shareholders

August 21st, 2016|

Patent Approval for BiondVax: BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel

December 21st, 2015|

BiondVax Receives Approval for Patent in Korea for its Universal Flu Vaccine

November 16th, 2015|

BiondVax Announces Upcoming Investor Events: Presenting at the LD Micro Conference in Los Angeles Following Investor non-deal Roadshow

November 4th, 2015|

Cytonvance Press Release: BiondVax Pharmaceuticals Selects Cytovance® Biologics for the Manufacturing of M-001 the Universal Flu Vaccine for Phase III Clinical Trials

November 3rd, 2015|

ביונדווקס גייסה בהצלחה מטופלים ראשונים לניסוי קליני שלב 2ב אירופה בחיסון האוניברסאלי לשפעת

October 21st, 2015|

BiondVax Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: Multimeric M-001

October 21st, 2015|

Unisec Press Release: UNISEC consortium including BiondVax started a clinical trial for a Universal Influenza Vaccine

October 16th, 2015|

Fierce Vaccines – BiondVax, EU’s UNISEC team up for universal flu jab Ph IIb

October 1st, 2015|

BiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials

October 1st, 2015|